NCEL
NewcelX Ltd.
NASDAQ · CHHealthcareBiotechnology
$3.96-3.30%
Price as of Jul 20, 2026
NCEL ownership
NewcelX Ltd. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
100/100
Buys (3m)
4
Sells (3m)
0
Net (3m)
$952.5K
Insiders buyingCluster buying
Context3-month price +102.4%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 29, 2026 | Samuel Olivierdirector | Buy | 81,818 | $2.75 |
| Apr 29, 2026 | Samuel Olivierdirector | Buy | 114,545 | $3.02 |
| Apr 29, 2026 | Revel Micheldirector, 10 percent owner, officer: CSO and Director | Buy | 54,545 | $2.75 |
| Apr 29, 2026 | Revel Micheldirector, 10 percent owner, officer: CSO and Director | Buy | 76,363 | $3.02 |
Source: NCEL SEC Form 4 filings, latest Apr 29, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their NCEL positions over the last 6 months (SEC Form 13F).
Increased
0
New positions
3
Reduced
0
Sold out
0
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| UBS GROUP AG | New Position | 684 | May 5, 2026 |
| TOWER RESEARCH CAPITAL LLC (TRC) | New Position | 147 | May 15, 2026 |
| CoreCap Advisors, LLC | Unchanged | 3 | Jul 6, 2026 |
| CORECAP ADVISORS, LLC | Unchanged | 3 | Apr 7, 2026 |
| CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | New Position | 1 | May 11, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.